Microbot net loss widens to $5.63 million in Q2 FY26; revenue rises to $241,000

Reuters2026/08/11 13:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Microbot posted a GAAP net loss of USD 5.63 million in Q2 2026, widening from USD 3.5 million a year earlier.
Revenue was USD 241,000, compared with no revenue a year earlier, as LIBERTY Endovascular Robotic System sales ramped post-launch.
Cost of revenues totaled USD 884,000, driven by manufacturing and commercialization costs tied to LIBERTY units for sale.
Sales, general and administrative expense climbed to USD 3.68 million from USD 1.61 million on higher payroll and commercialization-related spending.
Management reiterated it expects CE Mark approval for LIBERTY in the second half of 2026, while flagging ongoing Israel-region conflict risks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037009), on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Microbot net loss widens to $5.63 million in Q2 FY26; revenue rises to $241,000

You may also like

Crypto prices